HLN Stock Analysis: Buy, Sell, or Hold?
HLN - Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$10.16
0.15 (1.55%)
â˛
5d:
+6.0%
30d:
+3.83%
90d:
+9.31%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Get Alerted When HLN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: HLN is fairly priced but lacks strong directional signals. At -1.1% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: HLN is fairly priced but lacks strong directional signals. At -1.1% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$14.33
Based on 6.8% avg growth
INTRINSIC VALUE TODAY
$8.90
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HLN is currently trading at $10.15, which is considered slightly high relative to its 30-day fair value range of $9.74 to $10.07. The stock's valuation (Forward PE: 16.1) is in line with its historical norms (16.6). Remarkably, the market is currently pricing in an annual earnings decline of 1.1% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, HLN is in a strong downtrend. The price is approaching resistance at $10.03. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: HLN scores 61/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $11.99 (+19.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HLN is in a strong downtrend. The price is approaching resistance at $10.03. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: HLN scores 61/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $11.99 (+19.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$9.74 -
$10.07
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
73.8%
All Signals
- BULLISH: Strong technical setup (61/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($11.99)
- WARNING: Composite score 51/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$9.74 -
$10.07
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$9.57
Resistance Level
$10.03
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
16.05
Wall Street Target
$11.99
(+19.9%)
Revenue Growth (YoY)
2.2%
Earnings Growth (YoY)
-4.5%
Profit Margin
14.5%
Valuation Discount vs History
-1.1% cheaper
PE vs Historical
16.1 vs 16.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.1%
(market-implied from PE analysis)
1-Year Target
$9.89
(-1%)
2-Year Target
$9.78
(-2%)
3-Year Target
$9.67
(-3%)
3-Yr Target (if PE normalizes)
(PE: 16â17)
$10.01
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 9.5%)
$16.40
(+64%)
Base:
(SPY PE: 16.0, Growth: 9.5%)
$13.11
(+31%)
Bear:
(PE: 13.6, Growth: 9.5%)
$11.14
(+11%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (20x PE), but valuation improves significantly next year (16x PE) as earnings recover.
Trailing PE: 20.14 | Current EPS (TTM): $0.49
Bull Case
$13.81
(+38%)
Analyst growth 27.2%, PE expands to 22.2
Base Case
$12.55
(+26%)
Market implied 27.2%, PE stable at 20.1
Bear Case
$6.71
(-33%)
Severe decline -20.0%, PE contracts to 17.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 16.0 to 16.6
Stabilization Target:
$10.34
(+3.4%)
PE Expansion Potential:
+3.4%
Share & Embed Analysis
Last updated: August 24, 2026 11:42 AM ET
Data refreshes hourly during market hours. Next update: 12:42 PM
Data refreshes hourly during market hours. Next update: 12:42 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HLN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 56 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 43 HOLD |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$664 | 48 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 55 HOLD |
